Learn more about #CYB004: Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD: https://cybin.com/cyb004/ ↩️ #MentalHealthInnovation #Biotechnology
Small Pharma
Pharmaceutical Manufacturing
Short-duration psychedelics with therapy for under-served mental health conditions | TSXV:DMT | OTCQB: DMTTF
About us
Small Pharma is a biotech company taking a radically different approach to mental health treatment. We believe everyone deserves the option of better mental health. We are developing a pipeline of short-duration, psychedelic-assisted treatments for under-served mental health conditions, starting with the most advanced clinical trial in commercial development for DMT-assisted psychotherapy to treat Major Depressive Disorder.
- Website
-
https://smallpharma.com
External link for Small Pharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2015
Locations
-
Primary
Get directions
London, GB
Employees at Small Pharma
Updates
-
Learn more about #CYB004: Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD: https://cybin.com/cyb004/ ↩️ #MentalHealth #Biotechnology
-
-
Cybin welcomes Dr. Tom Macek to the R&D team! #MDD #MentalHealth #Biotechnology Amir Inamdar MBBS, DNB (Psych), FFPM
-
-
Learn more about #CYB004: Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD: https://cybin.com/cyb004/ ↩️ #MentalHealth #Biotechnology
-
Learn more about #CYB004: Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD: https://cybin.com/cyb004/ ↩️ #MentalHealth #Biotechnology
-
July is Bebe Moore Campbell National Minority Mental Health Awareness Month, a time to address and enhance minority access to mental health services. At Cybin, we’re focused on developing innovative new treatments to make mental health care more effective and accessible for all. Cybin Inc #MinorityMentalHealthMonth #NMMHAM #MentalHealth #Psychedeli
-
-
To date, Cybin has shared positive Phase 2 topline results for CYB003 in participants with Major Depressive Disorder #MDD, evaluating the efficacy and safety of CYB003 with two doses, at up to 4 months. Learn more: https://loom.ly/tZQcow0 ↩️ #researchanddevelopment #psychedelicresearch #clinicalresearch
-
#Cybin's #CYB003 received the first known U.S. #FDA Breakthrough Therapy Designation (#BTD) for an adjunctive psychedelic-based therapy for Major Depressive Disorder (#MDD) — validating its potential for significant clinical improvements over existing treatments and accelerating its development pathway towards commercialization. Learn more: https://lnkd.in/g2evfR-g #Biotechnology #MentalHealthInnovation #Psychedelics The recording shared below are the property of the OPEN Foundation and may not be shared without prior authorisation.
-
This #PrideMonth, Cybinauts are mindful of the disproportionate impact of mental health conditions on #LGBTQ2S+ communities and the urgency of realizing innovative new therapeutic options for all patients in need. Learn more: www.cybin.com #MentalHealth #Biotechnology #loveislove #Psychedelics #illustration #art #pride
-
Small Pharma reposted this
#Cybin has evolved into a mature, late-stage company with critical milestones on the near-term horizon. With #FDA #BTD designation and positive four-month durability data for #CYB003 and the initiation of our Phase 2 study of #CYB004, we are rapidly advancing our mission to change the treatment paradigm for #MDD and #GAD and bring innovative treatment options to patients in need. —Cybin CEO Doug Drysdale Read our full release on fiscal year 2024 and recent business highlights: https://loom.ly/4r6Nng0 #MentalHealthInnovation #Biotechnology #Psychedelics